je.st
news
Tag: with
KEYTRUDA (pembrolizumab) Shows Overall Response Rates of 73 to 83 Percent, with Complete Response Rates of 27 to 30 Percent, in Heavily Pre-treated Patients with cHL, in Update to Study KN-087
2016-06-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Findings Support Initiation of Phase 3 Pivotal Study (KEYNOTE-204) Evaluating KEYTRUDA Versus Brentuximab Vedotin in Relapsed or Refractory cHL KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings from KEYNOTE-087, the phase 2 study investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy in patients with relapsed or refractory classical Hodgkin lymphoma (cHL). These data will be presented today at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago from 8:00 11:30 a.m. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Updated Findings from KEYNOTE-012 for KEYTRUDA (pembrolizumab) Show Continued Benefit in Response Rates and Duration of Response Lasting Up to 30 Months in Patients with Previously Treated Recurrent or Metastatic Head and Neck Cancer
2016-06-06 14:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Response Rates from KEYNOTE-055 Show Nearly One in Five Patients Responding with KEYTRUDA; Results Confirm Findings from KEYNOTE-012 KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced new data with KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, as a monotherapy from two studies (KEYNOTE-012 and KEYNOTE-055) in heavily pre-treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Data are being presented at the 52nd Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558An Phan, 908-255-6325orInvestors:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Accelerating the Business Transformation with Consumer Lifecycle Insights while driving Enhanced engagement with RPA.
2016-06-04 18:00:00| Capgemini News Feed
Language Worldwide Sreekumar Vadakkepat Share: Share this page Alternate title: Engaging Consumer Journey: The magic for an ongoing consumer engagement lies in the ability to drive real time decisioning driven by INSIGHTS while driving enterprise agility with RPA
Tags: with
business
consumer
driving
Illinois Alderman Wants to Hold Neighborhood Meeting over Settlement with Advanced Disposal
2016-06-02 11:39:00| Waste Age
City officials and an environmental group of citizens are trying to figure out what to do about the settlement. read more
Tags: with
advanced
hold
meeting
06.08.16 -- How To Improve Profit Margins In Down Times With Innovative Water Management
2016-06-01 18:41:43| oilandgasonline News Articles
06/08/16 Oil and Gas Online Newsletter
Tags: with
times
management
water
Sites : [245] [246] [247] [248] [249] [250] [251] [252] [253] [254] [255] [256] [257] [258] [259] [260] [261] [262] [263] [264] next »